Our study demonstrated that the drug sensitivity of PDCs to targeting agents was closely associated with the patient’s tumor response; the drug sensitivity of the pretreatment PDC was strongly predictive of the clinical response to EGFR- or ALK-TKIs in patients with EGFR- or ALK-positive lung cancer. This evidence concerns the gene ALK and neoplasm.